• Research, Science, and Trials

  MOVE-FA Study for PTC-743

  Posted by christina-cordaro on April 1, 2021 at 7:48 am

  Enrollment is open at sites in the U.S., Canada, and Australia.

  MOVE-FA is a Phase 2/3 interventional study that will monitor the safety and efficacy of the drug Vatiquinone. This 2-year study is sponsored by PTC Therapeutics. Eligibility criteria include:

  -Genetically confirmed FA with two GAA repeat expansions (currently, point mutations and deletions are excluded from the study)
  -Children ages 7-17 and Adults age 18 and older
  -Ability to walk 10 feet in one minute (can use assitive devices of cane or walker; no wheelchair)
  -Be able to swallow capsules
  -Not have participated in another interventional study in the 2 months prior to enrollment in MOVE-FA

  Information on MOVE-FA and contacts for study coordinators can be found below: bit.ly/36YC9t6

  christina-cordaro replied 3 years ago 1 Member · 0 Replies

  • clinical study
  • enrollment
  • PTC Therapeutics
  • research
• 0 Replies

Log In to Reply